Co-Diagnostics (CODX) Tops Q1 EPS by 4c, Offers Q2 Guidance

Co-Diagnostics (NASDAQ: CODX) reported Q1 EPS of $0.26, $0.04 better than the analyst estimate of $0.22. Revenue for the quarter came in at $20 million versus the consensus estimate of $19.89 million.

GUIDANCE:

Co-Diagnostics sees Q2 2021 EPS of $0.19-$0.23, versus the consensus of $0.22. Co-Diagnostics sees Q2 2021 revenue of $20-22 million, versus the consensus of $16.3 million.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• After-Hours Stock Movers: FDX, CBRS, NKE
• Green Dot and CommerceOne shareholders approve acquisition deal